StockNews.AI
MNPR
StockNews.AI
112 days

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

1. MNPR's ALXN1840 data accepted for late-breaker presentation at EASL 2025. 2. EASL is a premier hepatology event in Amsterdam, May 7-10, 2025. 3. Late-breaker abstracts indicate high significance and rigorous selection process. 4. Presentation focuses on long-term efficacy and safety for Wilson disease patients. 5. Research visibility can enhance MNPR's market position and investor interest.

4m saved
Insight
Article

FAQ

Why Bullish?

Acceptance at EASL 2025 highlights potential for positive market reception. Historical instances show similar presentations often lead to stock price increases for biotech firms.

How important is it?

The article discusses a significant upcoming presentation that could influence MNPR's stock performance. Positive clinical outcomes at EASL can attract investors and improve sentiment.

Why Short Term?

The imminent EASL presentation is set for May 2025, promising immediate impact. Previous events have shown prompt market reactions post-presentation.

Related Companies

ALXNPTCTCLSD
WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease has been accepted for a late-breaker poster presentation at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025. EASL is recognized as one of the premier events in the hepatology space and will be held in Amsterdam, Netherlands from May 7 – 10, 2025. Late-breaker provides an opportunity to present “the most recent and significant findings,” according to EASL. Criteria for late-breaker abstracts include: (1) they present the latest, up-to-date research findings; (2) the research is considered highly significant with the potential to impact the field in a substantial manner; and (3) clinical studies should be prospective. Late-breaker abstracts undergo a rigorous review, and the acceptance rate is lower than regular abstracts with only the most compelling abstracts selected. Details of the EASL Congress 2025 late-breaker poster presentation are as follows: Title: Sustained long-term clinical improvement in Wilson disease patients on tiomolybdate choline Abstract Number: LB25251Session: Late-breaker PostersDate and Time: Wednesday, May 7, 8:30 a.m. CETPresenter: Karl Heinz Weiss, M.D. Location: Amsterdam, Netherlands The poster to be presented at EASL 2025 will be available online at www.monopartx.com on May 7, 2025. About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com. CONTACT: Monopar Therapeutics Inc.Investor Relations Quan Vu Chief Financial Officer vu@monopartx.com Follow Monopar on social media for updates: X: @MonoparTx  LinkedIn: Monopar Therapeutics

Related News